About Us

Intus Bio was founded with the goal of
solving three fundamental problems that were preventing practical use of the microbiome in healthcare. Our patent on bacterial lysis solves the problem of obtaining accurate representation of the strains in a sample, so that it is possible to accurately compare the relative quantities of the bacterial strains. The patented amplicon solves the problem of precise strain identification at scale, where there is sufficient genetic variability in the region for differentiation of strains, but at a sequencing scale that enables high-throughput analysis and rapid construction of a large database of reference samples from a diverse population. Proprietary analysis of the long amplicon data is facilitated by machine learning methods that allow precise statistical comparisons across our large population datasets, where each sample can be compare to the overall reference population to identify anomalous aspects of an individual’s microbial profile, for example, for potentially pathogenic bacterial signatures, as well as bacterial signatures associated with healthy populations. The third problem is the need for database independence, because the number of unknown species and strains associated with human health and disease likely ranges into the millions and billions of strains, where only tens of thousands of bacteria have been sequenced. The application of the unique, patented amplicon enables both identification and tracking of novel strains without relying on databases with far fewer than the millions of strains that would be required for traditional methods of ID and tracking.